NEWS & EVENTS

Hillstream BioPharma Acquires Novel Salinomycin-Analogs

Hillstream BioPharma Acquires Novel Salinomycin-Analogs FEBRUARY 10, 2020 Emerging Mechanism of Action: Ferroptosis – Strengthens Company’s Oncology Pipeline Chester, New Jersey, February 10, 2020 – Hillstream BioPharma Inc. (“Hillstream”), a near-clinical stage biotechnology company focused on rare, orphan and unmet need cancers announced today, acquisition of a salinomycin analogue portfolio with related global patents, non-clinical data, other…

Hillstream BioPharma to Present at Noble Capital’s Sixteenth Small and Micro Cap Conference

Hillstream BioPharma to Present at Noble Capital’s Sixteenth Small and Micro Cap Conference FEBRUARY 3, 2020 Chester, New Jersey, February 3, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in Noble Capital’s Sixteenth Small and Micro Cap Conference.  Hillstream will be providing updates on recent corporate developments as well as outlining near-term activities anticipated in 1H-2020.  Details about…

Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC)

Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC) January 6, 2020 Positive pre-clinical data with an emerging validated mechanism of action, Ferroptosis HSB-1216 is a novel therapeutic using the QUARTRAMER formulation of a potent anti-Ferroptotic compounds, Salinomycin Chester, New Jersey, January 6, 2020 – Hillstream BioPharma…

Hillstream BioPharma Announces Participation in the Biotech Showcase’s PartneringOne® System and Availability for Outside Appointments

Hillstream BioPharma Announces Participation in the Biotech Showcase’s PartneringOne® System and Availability for Outside Appointments January 2, 2020 Chester, New Jersey, January 2, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in the Biotech Showcase™’s one-to-one meeting system, partneringOne®.  The event will run from January 13-16, 2020.  One-on-one meetings booked through the partneringONE® system will be held…

Hillstream BioPharma to Present at the 12th Annual LDMicro 12th Main Event

Hillstream BioPharma to Present at the 12th Annual LDMicro 12th Main Event December 3, 2019 Chester, NJ – December 3, 2019 — Hillstream BioPharma Inc. (“Hillstream”) today announced that Chief Executive Officer, Randy Milby, will be presenting and meeting with investors at the 12th Annual LD Micro Annual Main Event Conference being held December 10-12,…

Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board

Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board November 19, 2019 Expertise in Small Cell Lung Cancer Supports Key Pipeline Drug – HSB: 1216 Chester, New Jersey, November 19, 2019 – Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific Advisory…

Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing

Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing November 4, 2019 Alignment Reinforces Hillstream BioPharma’s Strategy to Partner with Top-Tier Firms Chester, NJ – November 4, 2019 – Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for Hillstream’s QUATRAMER portfolio. This includes HSB-1216, a novel…

Hillstream BioPharma Featured on BioNJ’s, Emerging Company in the Spotlight

Hillstream BioPharma Featured on BioNJ’s, Emerging Company in the Spotlight October 10, 2019 BioNJ is pleased to shine the spotlight on one of our Innovation Members each month featuring their progress and work on behalf of Patients and their impact on the New Jersey life sciences ecosystem.  This month’s Emerging Company in the Spotlight is Hillstream BioPharma. …

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML October 10, 2019 Chester, NJ – October 10, 2019 — Hillstream BioPharma Inc. (“Hillstream”) today announced the renewal of a Cooperative Research and Development Agreement (CRADA) with the National Center…

Hillstream BioPharma Acquires Key Assets to Portfolio Including QUATRAMER Drug Delivery Technology Platform and Key Immuno-Oncology Compounds

Hillstream BioPharma Acquires Key Assets to Portfolio Including QUATRAMER Drug Delivery Technology Platform and Key Immuno-Oncology Compounds September 10, 2019 Acquisition Positions Hillstream as a Diversified Biotechnology Company Developing Novel, IND-Ready Immuno-Oncology Treatments for Orphan Tumors with Devastating and Unmet Need Chester, NJ — September 10, 2019 – Hillstream BioPharma Inc. (“Hillstream”) today announced the acquisition of…